Amgen bought ChemoCentryx ChemoCentryx from 10/20/22

User image

Vladimir Petenev

News editor
press@blackterminal.com

Amgen completed its acquisition of ChemoCentryx for $3.7 billion, or $52 per share.

ChemoCentryx

Review

Source:

{source} pictogram

investors.amgen.com

Vladimir Petenev

News editor

Write your comment first

News feed

Cherkizovo Group reported for 6 months of 2023 by RAS

7/18/23 GCHE

RussNeft reported for 6 months of 2023 by RAS

7/18/23 RNFT

OGK-2's output in 1H increased by 5.7%

7/18/23 OGKB

The Morgan Stanley announced a quarterly dividend

7/18/23 MS

Morgan Stanley reported for 6 months of 2023

7/18/23 MS

Lockheed Martin reported for 6 months of 2023

7/18/23 LMT

Bank of America reported for 6 months of 2023

7/18/23 BAC

MMK's sales in 1H increased by 11.1%

7/18/23 MAGN

X5 Group revenue in first half of the year increased by 17.5%

7/18/23 -

SPB Exchange is thinking about participating in the creation of a crypto-exchange

7/18/23 SPBE